Metrics to compare | TECX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTECXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.6x | −3.6x | −0.2x | |
PEG Ratio | 0.24 | −0.02 | 0.00 | |
Price / Book | 1.8x | 4.7x | 2.6x | |
Price / LTM Sales | - | 16.1x | 2.6x | |
Upside (Analyst Target) | 242.5% | 272.5% | 77.0% | |
Fair Value Upside | Unlock | 10.2% | 13.7% | Unlock |
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company’s lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.